Full-Time

Territory Business Representative

Deadline 4/7/27
Xeris Pharmaceuticals

Xeris Pharmaceuticals

201-500 employees

Develops ready-to-use liquid-stable injectables

Compensation Overview

$85k - $140k/yr

+ Commission + Equity

Union City, NJ, USA

In Person

Minimum travel 20%; vehicle travel required.

Category
Sales & Account Management (1)
Required Skills
Sales
Marketing
Requirements
  • Bachelor’s Degree in Health Sciences, Business/Marketing, or related field.
  • 2+ years of experience in field commercial positions, including but not limited to: sales representative, hospital representative, sales trainer, and marketing (Sales Representative)
  • 5+ years of experience in bioscience commercial positions, including but not limited to: sales representative, hospital representative, sales training, marketing and regional account manager (Sr. Sales Representative)
  • A valid, US State-issued driver’s license is required
Responsibilities
  • Deliver on corporate objectives specific to territory.
  • With RBD and internal business partner input, develop, evolve, and execute territory and account level business plans.
  • Engage RBD with timely recommendations to eliminate or minimize barriers to progress specific to marketplace trends, business opportunities and threats, competitive information, etc.
  • Leverage internal expertise to maximize field impact.
  • Work with Regional Business Directors, Channel/Trade & Market Access Teams, and Sales Representatives to develop territory-specific strategies to ensure patient access to Xeris products.
  • Manage territory budget and resource allocations to maximize return on investment.
  • Create a face to the internal and external customer that demonstrates Xeris’ commitment to bringing value and solutions to the customers and patients we serve.
  • Collaborate with peers, marketing, and training personnel to share information and implement territory initiatives/strategies.
  • Create, build, and maintain relationships and regular communications and sales efforts with physicians & other health care providers, and all others pertinent to Xeris’ business.
  • Professionally and ethically represent Xeris to external customers (including but not limited to hospitals, IDNs, individual physicians and health care providers, and local diabetes chapters) and foster their respect by demonstrating our commitment to advancing patient care and outcomes.
  • Professionally and ethically represent Xeris internally and foster professionalism within, among, and beyond the region.
  • Take responsibility for ongoing professional development to maximize effectiveness in advancing Xeris’ objectives.
  • Leverage internal training and development.
  • Refine ability to navigate complex and multi-layered accounts
  • Refine ability to effectively communicate and engage with customers while leveraging Xeris internal resources.
Desired Qualifications
  • Recent experience in bioscience and/or diabetes is highly desirable
  • Proficient in understanding key data and metrics and utilizing this information to improve business performance
  • Thrives in ambiguity and uncertainty; can adapt quickly in any situation and asks questions to increase depth of understanding
  • Competencies: Self-directed, Organizational skills, Verbal and Written Communication skills, Time Management, Presentation skills, Project Management skills, Problem Solving, Negotiation skills, Influencer, Adaptability
Xeris Pharmaceuticals

Xeris Pharmaceuticals

View

Xeris Biopharma Holdings develops ready-to-use, liquid-stable injectables for serious conditions, using its XeriSol and XeriJect platforms. Their products come in prefilled syringes or devices that do not require mixing or refrigeration, enabling smaller injections and quick administration. The company differentiates itself by delivering stable, ready-to-use formulations focused on rare diseases and endocrinology, supported by a U.S.-based field force and a portfolio that includes Gvoke, Keveyis, and Recorlev. Its goal is to expand access to simple, stable injectable therapies and grow its pipeline across endocrinology, neurology, and gastroenterology through its proprietary technologies.

Company Size

201-500

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

2005

Simplify Jobs

Simplify's Take

What believers are saying

  • Recorlev revenue nearly doubled to $50M in Q1 2026 with 60% therapy-naïve patient starts.
  • ADA 2025 Standards explicitly recommend ready-to-use glucagon formulations, validating Gvoke positioning.
  • XP-8121 Phase 3 initiation in late 2026 targets $1B–$3B peak sales by 2035.

What critics are saying

  • Eli Lilly Baqsimi captures 65% glucagon market share; Gvoke revenue flat at $20.8M Q1 2026.
  • Medicare Part D redesign favors lowest-price glucagon options, sustaining Gvoke revenue pressure indefinitely.
  • CEO Paul Edick retires August 1, 2026; leadership transition disrupts Recorlev commercial expansion momentum.

What makes Xeris Pharmaceuticals unique

  • XeriSol and XeriJect platforms enable room-temperature stable, ready-to-use injectable formulations without reconstitution.
  • Diversified rare disease portfolio: Recorlev, Gvoke, Keveyis, and Ogluo across endocrinology and neurology.
  • Achieved profitability in 2025 with $60M adjusted EBITDA and 44% revenue growth year-over-year.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Xeris Pharmaceuticals who can refer or advise you

Benefits

Health Insurance

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 2nd, 2026
Xeris Biopharma achieves profitability with $60M adjusted EBITDA, eyes 30% growth in 2026

Xeris Biopharma achieved financial self-sustainability in 2025, reporting its first full year of net income and nearly $60 million in adjusted EBITDA. The company posted 44% revenue growth, driven by its three commercial products, with Recorlev nearly doubling its patient base to approximately 700 patients. For 2026, Xeris has issued revenue guidance of $375 million to $390 million, representing over 30% growth. The company plans to initiate a Phase III trial for XP-8121 in the second half of 2026, requiring a $25 million increase in R&D spending. Xeris filed patent infringement lawsuits against two generic drug applicants to protect Recorlev patents extending to March 2040. Management maintains peak sales expectations of $1 billion for Recorlev by 2035 and $1 billion to $3 billion for XP-8121.

Yahoo Finance
Mar 2nd, 2026
Xeris Biopharma beats Q4 estimates with $85.8M revenue, forecasts up to $390M for 2025

Chicago-based Xeris Biopharma Holdings reported fourth-quarter earnings of $11.1 million, or 6 cents per share, surpassing Wall Street expectations of 3 cents per share. Revenue reached $85.8 million, exceeding analyst forecasts of $81.4 million. For the full year, the company reported profit of $554,000 with revenue of $291.8 million. Xeris Biopharma expects full-year revenue between $375 million and $390 million. The results beat expectations across all metrics surveyed by Zacks Investment Research.

Association of Diabetes Care and Education Specialists
Aug 10th, 2025
ADCES names Katelyn O'Brien 2026 Diabetes Care and Education Specialist of the Year

I wish to extend my gratitude to those that nominated me, the ADCES Awards Committee, and Xeris Pharmaceuticals for their continued support for this award.

BioSpace
Mar 31st, 2025
Xeris Announces Changes to Its Board of Directors

The Board of Directors has appointed James Brady as a new director of Xeris' board to fill the vacancy.

ETF Daily News
Mar 29th, 2025
Cibc World Markets Corp Invests $44,000 in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Cibc World Markets Corp invests $44,000 in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS).